ESTRO 35 2016 S705 ________________________________________________________________________________ collimator angle. The results are based on the value of GAI: when the value is lower than 95%, the error is detected. Introduced errors are smaller and smaller in order to characterize error detection limits of each method. For Portal Dosimetry, it is possible to detect errors of collimator angle up to 4° and errors of Monitor Units up to 3%. For Delta4, it is possible to detect errors of collimator angle up to 2° and errors of Monitor Units up to 2 %. For Epiqa, it is possible to detect errors of collimator angle up to 2° and errors of Monitor Units up to 3%.
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Conclusion:
In spite of their differences, the three pretreatment verification methods are able to detect different sort of errors in dose distributions. The comparative study gives us concordant results. Therefore, these data suggest the possibility of using only one routinely and complete the analysis with one of the other in case of problems.
EP-1522
Evaluation of usefulness of patient dose analysis system using MLC log file C. In this study, we compared patient therapy planning evaluation system, applying MLC log file, with quality assurance system using the fluence map obtained from measurement, in order to assess usefulness of patient dose analysis system.
Material and Methods:
To map out IMRT treatment planning, we used 4 targets and organ contours (multiple targets, virtual prostate, virtual head & neck, C type), along with IMRT phantom as presented in AAPM TG-119 Report. The treatment planning was implemented via Eclipse treatment planning system using 7 radiation field at an interval of 50º from 0o for both multiple targets and virtual prostate on one hand and using 9 radiation fields at an interval of 40º from 0o for both virtual head & neck and C type on the other hand. For dose limitation conditions for PTV and critical structure, we adopted the objectives specified in TG 119 Report. In relation to dose evaluation, point dose was evaluated by using CC13 chamber. The gamma index was analyzed for allowable limit of 3%/3mm by using MobiusFx system, a dose analysis software using MLC log file, in tandem with 2D array detector and Compass software that evaluates dose based on fluence map.
Results: Dose distribution was calculated using treatment planning and Mobius system for 4 targets and then compared through three-dimensional gamma index based on the setting criteria for allowable limit of 3%/3mm. The results showed the pass rate of 99.5% in multiple targets, 100.0% in prostate, 99.5% in head & neck, and 99.8% in C type. Based on results of analysis of gamma index for dose distribution, which was performed on the basis of dose distribution calculated by MobiusFX system and MLC log file actually investigated, the pass rate was found to be 100.0% in multiple targets, 100.0% in prostate, 99.7% in head & neck, and 99.5% in C type. Meanwhile, gamma index was analyzed based on dose distribution under treatment planning for 4 targets and dose distribution measured through Compass system, and the results indicated that the pass rate was 99.9% in multiple targets, 99.6% in prostate, 99.2% in head & neck, and 98.8% in C type. In addition, the results of point dose evaluation, performed based on point dose under treatment planning using CC13 chamber and point dose actually measured, showed that difference in pass rate was 1.2% in multiple targets, 1.5% in prostate, 1.3% in head & neck, and 0.4% in C TYPE.
Conclusion:
This study may provide useful basis for ensuring quality assurance for each patient by using the MLC log analysis system during special treatments in clinical applications. Purpose or Objective: The aim of this study was to assess the accuracy of the dosimertic algorithm based on the resolution of Boltzmann equation: "Acuros XB" (AXB) implemented in Eclipse (Varian) TPS. The methodology recommended by the IAEA-TECDOC-1583 was followed to evaluate AXB. AXB was also tested for clinical extra cranial stereotactic treatment cases. Moreover AXB with the two absorbed dose reporting options, dose-to-medium (Dm) and dose-to-water (Dw), was compared against the Analytical Anisotropic Algorithm (AAA).
EP-1523 Validation of the dosimetric algorithm Acuros XB and the impact of its usage in SBRT treatments

Material and Methods:
The IAEA-TECDOC-1583 presents eight different fields configurations in heterogeneous media. All plans were created on a CIRS thorax phantom model 002LFC including different tissue equivalent inserts (water, bone and lung). Measurements were performed with a PinPoint ionization chamber (type 31016, PTW) on Novalis TrueBeam STx accelerator for 6MV and 10MV photons with and without flattening filter (6FF, 6FFF, 10FF, 10FFF). Furthermore, target absorbed dose difference between AXB (Dm and Dw) and AAA were compared using same monitor units for 17 patients with non-small-cell lung cancer (NSCLC) or bone metastases cancer who underwent SBRT.
Results: AXB Dm calculations showed an excellent agreement with measurements for the eight configurations of the IAEA-TECDOC-1583. All the results fulfilled the agreement criterion given in the IAEA-TECDOC-1583. The biggest difference between measured and calculated absorbed dose with AXB (Dm and Dw) in lung was less than 0.6% for all photon energies. Unlike, in the lung region, AAA showed deviations that didn't met the agreement criterion. Maximum deviations were 4.4%, 3.35%, 2.27% and 1.6% for respectively 6FF, 10FF, 6FFF and 10FFF photon energies. Although the Dm and Dw was almost the same in most tissues for all the energies, comparing them in bony structure didn't give similar results. When choosing Dw in the bone region some results didn't fulfilled the agreement criterion, unlike Dm where excellent agreement were found between calculated and measured absorbed dose. For the planning target volume (PTV) in the NSCLC patients, AXB Dm and Dw calculations showed similar results while compared to the AAA calculations, where the average differences were less than 2% for minimum, mean and maximum absorbed doses. For bone metastases cancer patients, comparing the PTV doses between AXB Dm and AXB Dw didn't show similar results. The averaged deviations between AXB Dm and AAA were 1.7%, 0.1% and 2.2% whereas deviations between AXB Dw and AAA were 0.1%, 4.2% and 0.7%, respectively for minimum, maximum and mean absorbed doses.
Conclusion:
The results of the IAEA-TECDOC-1583 and of clinical cases showed that the AXB algorithm is more accurate than AAA in the lung region for 6FF, 10FF, 6FFF and 10FFF photons. As for bone metastasis the use of AXB Dm was recommended.
EP-1524
The effect of the 
